Premium
Haemodialysis does not affect the pharmacokinetics of nifedipine.
Author(s) -
Martre H.,
Sari R.,
Taburet AM,
Jacobs C.,
Singlas E.
Publication year - 1985
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1985.tb05049.x
Subject(s) - nifedipine , pharmacokinetics , medicine , dialysis , oral administration , urology , half life , kidney disease , hemodialysis , pharmacology , calcium
To establish dosage recommendations in patients with end‐stage renal disease undergoing chronic haemodialysis, nifedipine kinetics were studied between and during haemodialysis sessions. In eight patients, during the interdialytic period, peak plasma concentrations of nifedipine (29‐332 ng/ml) were reached 0.5‐1.0 h after administration of a single 10 mg oral dose. Elimination half‐life and oral plasma clearance were respectively 2.6 +/‐ 0.5 h and 1 176 +/‐ 412 ml/min. Nifedipine plasma protein binding was decreased in uraemic patients (88.8 +/‐ 0.3% vs 94.4 +/‐ 0.1%) but not affected by haemodialysis. Removal by haemodialysis was low: the dialyser extraction ratio and the dialysis clearance were respectively 2.3 +/‐ 0.8% and 2.8 +/‐ 0.9 ml/min.